465 related articles for article (PubMed ID: 19238094)
1. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
3. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
4. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Rice JP; Skagen C; Said A
Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin and albumin combination treatment in hepatorenal syndrome.
Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
[TBL] [Abstract][Full Text] [Related]
7. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
Tandon P; Tsuyuki RT; Mitchell L; Hoskinson M; Ma MM; Wong WW; Mason AL; Gutfreund K; Bain VG
Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
[TBL] [Abstract][Full Text] [Related]
8. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
9. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.
Kiser TH; Fish DN; Obritsch MD; Jung R; MacLaren R; Parikh CR
Nephrol Dial Transplant; 2005 Sep; 20(9):1813-20. PubMed ID: 15956066
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
Salerno F; Cazzaniga M; Merli M; Spinzi G; Saibeni S; Salmi A; Fagiuoli S; Spadaccini A; Trotta E; Laffi G; Koch M; Riggio O; Boccia S; Felder M; Balzani S; Bruno S; Angeli P;
J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
[TBL] [Abstract][Full Text] [Related]
15. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
Esrailian E; Pantangco ER; Kyulo NL; Hu KQ; Runyon BA
Dig Dis Sci; 2007 Mar; 52(3):742-8. PubMed ID: 17235705
[TBL] [Abstract][Full Text] [Related]
16. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
17. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
18. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Testro AG; Wongseelashote S; Angus PW; Gow PJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
